Analysis on Current Situation and Trend of FDA's Risk Evaluation and Mitigation Strategy

Chinese Journal of Pharmacovigilance ›› 2013, Vol. 10 ›› Issue (4): 210-214.

Previous Articles Next Articles

Analysis on Current Situation and Trend of FDA's Risk Evaluation and Mitigation Strategy

ZHAO Pin ,XU Mei-ting, YANG Yue

College of Business Administration, Shenyang Pharmaceutical University Liaoning Shenyang 110016, China

Received:2013-03-08 Revised:2016-03-09 Online:2013-04-08 Published:2016-03-09

Abstract

ZHAO Pin ,XU Mei-ting, YANG Yue. Analysis on Current Situation and Trend of FDA's Risk Evaluation and Mitigation Strategy [J]. Chinese Journal of Pharmacovigilance, 2013, 10(4): 210-214.

[1]	ZHENG Chao, WU Yan, ZHANG Lan, HU Kai, ZENG Ye, WANG Wen, WANG Ling. Methods for risk trend analysis of EU post-marketing surveillance for medical devices [J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 79-82.
[2]	WANG Xiao, HE Xuan, DAI Huizhen, LI Xin, HAN Feng. Market Competition Trends of Innovative Anti-tumor Drugs in Nanjing Based on Terminal Data [J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 731-736.
[3]	WANG Dan, REN Jingtian, DONG Duo, PENG Lili, LIU Wei. Trend Analysis of Ten-year Annual Reports on Adverse Drug Reaction Monitoring [J]. Chinese Journal of Pharmacovigilance, 2020, 17(5): 276-283.
[4]	HUANG Gui-hua,DU Hua-rong,GONG Li-kun. Analysis on Global Research Trends of Pharmacovigilance in Recent Five Years and Its Implications for China [J]. Chinese Journal of Pharmacovigilance, 2018, 15(5): 268-275.
[5]	SHEN Lu, LIU Wei, GUO Xue, PENG Li-li, KONG Fan-yao, LI Xin-ling. Ideas on Trend of ADR Monitoring Model in China [J]. Chinese Journal of Pharmacovigilance, 2017, 14(5): 295-297.
[6]	LI Shu -fang, PAN Wen -hao. The Introduction and Inspiration of Risk Evaluation and Mitigation Strategies in the Unite State [J]. Chinese Journal of Pharmacovigilance, 2013, 10(5): 283-285.
[7]	LI Shu -fang, PAN Wen -hao. The Study and Development of FDA Drug Risk Management Plan in View of Specific Drug [J]. Chinese Journal of Pharmacovigilance, 2013, 10(3): 144-147.
[8]	ZHAO Pin ,BIAN Lei ,YANG Yue. FDA's Risk Evaluation and Mitigation Strategy and the Inspirations to Our Country [J]. Chinese Journal of Pharmacovigilance, 2013, 10(3): 140-134.
[9]	BIAN Bo-yang, GUO Jian-fei. The Impact of FDA Amendment Act 2007 to US Pharmaceutical Industry in US and the Enlightenment to Drug safety Surveillance System in China [J]. Chinese Journal of Pharmacovigilance, 2010, 7(4): 221-223.

Analysis on Current Situation and Trend of FDA's Risk Evaluation and Mitigation Strategy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 9

Recommended Articles

Metrics